STAT3 and cancer: For example, it has been reported that other agents, including JAK inhibitor, the direct activator of STAT3, can also synergize with Sorafenib to inhibit cancer progression44 as well as molecules YC‐145 and SC‐5946 to enhance SHP1 to enhance STAT3 dephosphorylation.